Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy

Journal of Clinical Virology

Volumn 50, Issue 4, 2011, Pages 287-291

  Chou, Sunwen ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cytomegalovirus; Mutation; Phenotyping; Polymerase; Resistance

Indexed keywords

ALKALINE PHOSPHATASE; CIDOFOVIR; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; SECRETED ALKALINE PHOSPHATASE; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA RECOMBINATION; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSFECTION; GENETIC VARIABILITY; GENOTYPE; GROWTH INHIBITION; MOLECULAR CLONING; MUTAGENICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; VIRUS RECOMBINANT;

ANTIVIRAL AGENTS; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FOSCARNET; GANCICLOVIR; GENOMIC STRUCTURAL VARIATION; HUMANS; MUTATION; PHENOTYPE; VIRAL PROTEINS;

EID: 79952618827     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.01.004     Document Type: Article

References (25)

1. Kotton C.N., Kumar D., Caliendo A.M., Asberg A., Chou S., Snydman D.R., et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010, 89:779-785.
2. Lurain N.S., Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010, 23:689-712.
3. Chou S., Lurain N.S., Thompson K.D., Miner R.C., Drew W.L. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003, 188:32-39.
4. Cihlar T., Fuller M.D., Cherrington J.M. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol 1998, 72:5927-5936.
5. Chou S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Chemother 2010, 54:2371-2378.
6. Chou S., Van Wechel L.C., Lichy H.M., Marousek G.I. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother 2005, 49:2710-2715.
7. Warming S., Costantino N., Court D.L., Jenkins N.A., Copeland N.G. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 2005, 33:e36.
8. Chou S. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob Agents Chemother 2009, 53:81-85.
9. Chou S., Marousek G.I., Van Wechel L.C., Li S., Weinberg A. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob Agents Chemother 2007, 51:4160-4162.
10. Chou S., Van Wechel L.C., Marousek G.I. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J Infect Dis 2007, 196:91-94.
11. Humar A., Kumar D., Preiksaitis J., Boivin G., Siegal D., Fenton J., et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 2005, 5:1462-1468.
12. Lurain N.S., Bhorade S.M., Pursell K.J., Avery R.K., Yeldandi V.V., Isada C.M., et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002, 186:760-768.
13. Oshima K., Kanda Y., Kako S., Asano-Mori Y., Watanabe T., Motokura T., et al. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes. J Med Virol 2008, 80:1769-1775.
14. Cherrington J.M., Fuller M.D., Lamy P.D., Miner R., Lalezari J.P., Nuessle S., et al. In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome. J Infect Dis 1998, 178:1821-1825.
15. Scott G.M., Weinberg A., Rawlinson W.D., Chou S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother 2007, 51:89-94.
16. Springer K.L., Chou S., Li S., Giller R.H., Quinones R., Shira J.E., et al. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol 2005, 43:208-213.
17. Mousavi-Jazi M., Schloss L., Drew W.L., Linde A., Miner R.C., Harmenberg J., et al. Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity. J Clin Virol 2001, 23:1-15.
18. Chevillotte M., Ersing I., Mertens T., von Einem J. Differentiation between polymorphisms and resistance associated mutations in the human cytomegalovirus DNA polymerase. Antimicrob Agents Chemother 2010, 54:5004-5011.
19. Chou S., Marousek G., Parenti D.M., Gordon S.M., LaVoy A.G., Ross J.G., et al. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. J Infect Dis 1998, 178:526-530.
20. Chou S., Marousek G., Guentzel S., Follansbee S.E., Poscher M.E., Lalezari J.P., et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997, 176:786-789.
21. Mousavi-Jazi M., Schloss L., Wahren B., Brytting M. Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase. J Clin Virol 2003, 26:301-306.
22. Baldanti F., Underwood M.R., Stanat S.C., Biron K.K., Chou S., Sarasini A., et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996, 70:1390-1395.
23. Chou S., Marousek G., Li S., Weinberg A. Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. J Clin Virol 2008, 43:107-109.
24. Chou S., Marousek G., Boivin G., Goyette N., Farhan M., Ives J.A.L., et al. Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. Transplantation 2010, 90:1409-1413.
25. Boivin G., Goyette N., Rollag H., Jardine A.G., Pescovitz M.D., Asberg A., et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009, 14:697-704.